Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

 Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

Shots:

  • The company received DCGI’s MA for Teriparatide (biosimilar) for the treatment of Osteoporosis vs anti-resorptive therapies such as bisphosphates and SERMs
  • The approved product will be marketed through Alkem Laboratories as well as it explore other potential partnering opportunities
  • Teriparatide will be launched in a fully compliant pen device

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post